| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | NME抑制剂以及应用NME抑制剂的方法 | CN201480022551.6 | 2014-02-20 | CN105229027A | 2016-01-06 | 辛西娅·巴姆达德; 贝努瓦·斯马格 |
| 本申请公开了蛋白质的NME家族的抑制剂。 | ||||||
| 2 | 線維症治療において有用な分子標的及び前記標的のインヒビター | JP2015562042 | 2014-03-07 | JP2016518812A | 2016-06-30 | アントニウス ジョゼフ ジャンセン リチャード; ニコレテ レケルケルケル アンマリ; アルビオウ ジャミル; オウウエハンド クリスタ |
| 本発明は、線維化状態、特に線維芽細胞遊走及び分化に関連した疾患の治療において有用な物質を同定する方法及びアッセイに関する。本発明は、ポリペプチド及び核酸標的物、これらの標的物を基にしたsiRNA配列及び標的物に対する抗体を提供する。本発明は更に、線維化状態の治療における使用のための、標的物を基にしたsiRNA配列及び標的物に対する抗体を含有する医薬組成物に関する。本発明は更に、線維芽細胞遊走及び分化を阻害するインビトロ方法を提供する。【選択図】図1 | ||||||
| 3 | Methods of identifying compounds for the treatment of fibrosis by using S1PR5 | US14775828 | 2014-03-07 | US09952202B2 | 2018-04-24 | Richard Antonius Jozef Janssen; Annemarie Nicolete Lekkerkerker; Jamil Aarbiou; Krista Ouwehand |
| The present invention relates to methods and assays for identifying agents useful in the treatment of fibrotic diseases, in particular diseases related to fibroblast migration and differentiation. The invention provides polypeptide and nucleic acid TARGETs, siRNA sequences based on these TARGETs and antibodies against the TARGETs. The invention is further related to pharmaceutical composition comprising siRNA sequences based on the TARGETs and antibodies against the TARGETs for use in the treatment of fibrotic disease. The invention further provides in vitro methods for inhibition of fibroblast migration and differentiation. | ||||||
| 4 | Reduction of lipase activity in product formulations | US15105925 | 2014-12-18 | US09932591B2 | 2018-04-03 | Kelvin Lee; Abraham Lenhoff; Kristin Valente; Nick Levy; Yatin Gokarn |
| The invention relates a method for producing a stable recombinant protein, comprising growing a non-naturally occurring host cell in a culture medium to produce a recombinant protein, and making a composition comprising the recombinant protein and a polysorbate. The production of endogenous lipoprotein lipase by the host cell is reduced. The endogenous lipoprotein lipase is present in the composition in a small amount, and is capable of degrading the polysorbate. The invention also relates to the relevant host cells and compositions, and preparation thereof. | ||||||
| 5 | CELL-FREE PRODUCTION OF RIBONUCLEIC ACID | US15480617 | 2017-04-06 | US20170292138A1 | 2017-10-12 | William Jeremy Blake; Drew S. Cunningham; Daniel MacEachran; Mehak Gupta; James Robbins Abshire |
| Provided herein, in some aspects, are methods and compositions for cell-free production of ribonucleic acid. | ||||||
| 6 | NME Inhibitors and Methods of Using NME Inhibitors | US15910894 | 2018-03-02 | US20180258186A1 | 2018-09-13 | Cynthia Bamdad; Benoit Smagghe |
| The present application discloses inhibitors of NME family of proteins. | ||||||
| 7 | REDUCTION OF LIPASE ACTIVITY IN PRODUCT FORMULATIONS | US15897290 | 2018-02-15 | US20180179545A1 | 2018-06-28 | Kelvin LEE; Abraham Lenhoff; Kristin Valente; Nick Levy; Yatin Gokarn |
| The invention relates a method for producing a stable recombinant protein, comprising growing a non-naturally occurring host cell in a culture medium to produce a recombinant protein, and making a composition comprising the recombinant protein and a polysorbate. The production of endogenous lipoprotein lipase by the host cell is reduced. The endogenous lipoprotein lipase is present in the composition in a small amount, and is capable of degrading the polysorbate. The invention also relates to the relevant host cells and compositions, and preparation thereof. | ||||||
| 8 | REDUCTION OF LIPASE ACTIVITY IN PRODUCT FORMULATIONS | US15105925 | 2014-12-18 | US20160312226A1 | 2016-10-27 | Kelvin LEE; Abraham LENHOFF; Kristen VALENTE; Nick LEVY; Yatin GOKARN |
| The invention relates a method for producing a stable recombinant protein, comprising growing a non-naturally occurring host cell in a culture medium to produce a recombinant protein, and making a composition comprising the recombinant protein and a polysorbate. The production of endogenous lipoprotein lipase by the host cell is reduced. The endogenous lipoprotein lipase is present in the composition in a small amount, and is capable of degrading the polysorbate. The invention also relates to the relevant host cells and compositions, and preparation thereof. | ||||||
| 9 | METHOD FOR INDUCING CELLS TO LESS MATURE STATE | US14596051 | 2015-01-13 | US20150320840A1 | 2015-11-12 | Cynthia BAMDAD |
| The present application describes a method for inducing or maintaining pluripotency in a cell by contacting the cell with a biological or chemical species that increases MUC1* activity. | ||||||
| 10 | ＮＭＥ阻害剤、及びＮＭＥ阻害剤を使用する方法 | JP2015558975 | 2014-02-20 | JP2016514099A | 2016-05-19 | バンダッド，シンシア; スマッジ，ブノワ |
| 本願発明は、タンパク質のNMEファミリーの阻害剤である。 | ||||||
| 11 | より未分化状態への細胞の誘導方法 | JP2015521887 | 2013-07-15 | JP2016502399A | 2016-01-28 | バンダッド，シンシア |
| 本願発明は、MUC1*活性を増加させる細胞を生物学的又は化学的種と接触させることにより、細胞の多分化能を導く又は維持する方法に関する。 | ||||||
| 12 | NME Inhibitors and Methods of Using NME Inhibitors | US14831825 | 2015-08-20 | US20160326263A1 | 2016-11-10 | Cynthia Bamdad; Benoit Smagghe |
| The present application discloses inhibitors of NME family of proteins. | ||||||
| 13 | MOLECULAR TARGETS AND COMPOUNDS, AND METHODS TO IDENTIFY THE SAME, USEFUL IN THE TREATMENT OF FIBROSIS | US14775828 | 2014-03-07 | US20160069868A1 | 2016-03-10 | Richard Antonius Jozef JANSSEN; Annemarie Nicolete LEKKERKERKER; Jamil AARBIOU; Krista OUWEHAND |
| The present invention relates to methods and assays for identifying agents useful in the treatment of fibrotic diseases, in particular diseases related to fibroblast migration and differentiation. The invention provides polypeptide and nucleic acid TARGETs, siRNA sequences based on these TARGETs and antibodies against the TARGETs. The invention is further related to pharmaceutical composition comprising siRNA sequences based on the TARGETs and antibodies against the TARGETs for use in the treatment of fibrotic disease. The invention further provides in vitro methods for inhibition of fibroblast migration and differentiation. | ||||||
| 14 | METHOD FOR ENHANCING TUMOR GROWTH | US14468106 | 2014-08-25 | US20150089677A1 | 2015-03-26 | Cynthia BAMDAD |
| The present application discloses a method of testing for efficacy of a potential drug agent against cancerous cells in a mammal, including generating the cancer cells in a mammal; contacting the cancer cells with a potential drug agent by administering the potential drug agent to the mammal; and measuring effect of the potential drug agent on the cancer cells, wherein reduction of number of cancer cells in the mammal is indicative of efficaciousness of the potential drug agent against cancerous cells. | ||||||
| 15 | EXTRACTS ISOLATED FROM ELECTROPORATED AMBHIBIAN OOCYTES AND USE THEREOF IN TREATING DISEASES AND DISORDERS | US13949977 | 2013-07-24 | US20140030244A1 | 2014-01-30 | Sergei Paylian |
| The described invention provides methods for preparing a composition containing extracts of activated amphibian oocytes, the method where the composition is a pharmaceutical composition comprising an equal volume of the extra-oocyte composition and the intra-oocyte composition, and a method for treating a disease, disorder, condition or injury characterized by a damaged or a cancerous differentiated cell including: (a) preparing the composition by the described method; (b) formulating a pharmaceutical composition comprising an equal volume of the extra-oocyte composition and the intra-oocyte composition, and optionally a carrier; and (c) administering a therapeutic amount of the pharmaceutical composition of (b) to a subject in need thereof, where the therapeutic amount is effective to reprogram the damaged or cancerous cells into iPSC-like cells capable of differentiating into cells capable of repairing the damaged or cancerous cells, thereby treating the disease, disorder, injury or condition. | ||||||
| 16 | REPROGRAMMING CANCER CELLS | US13162558 | 2011-06-16 | US20120156246A1 | 2012-06-21 | CYNTHIA C. BAMDAD |
| The present application describes a method of treating a patient with cancer or at risk of developing cancer with at least one regulatory element that induces differentiation of cells. | ||||||
| 17 | MOLECULAR TARGETS AND COMPOUNDS, AND METHODS TO IDENTIFY THE SAME, USEFUL IN THE TREATMENT OF FIBROSIS | EP14708866.0 | 2014-03-07 | EP2972380A2 | 2016-01-20 | JANSSEN, Richard Antonius Jozef; LEKKERKERKER, Annemarie Nicolette; AARBIOU, Jamil; OUWEHAND, Krista |
| The present invention relates to methods and assays for identifying agents useful in the treatment of fibrotic diseases, in particular diseases related to fibroblast migration and differentiation. The invention provides polypeptide and nucleic acid TARGETs, siRNA sequences based on these TARGETs and antibodies against the TARGETs. The invention is further related to pharmaceutical composition comprising siRNA sequences based on the TARGETs and antibodies against the TARGETs for use in the treatment of fibrotic disease. The invention further provides in vitro methods for inhibition of fibroblast migration and differentiation. | ||||||
| 18 | NME INHIBITORS AND METHODS OF USING NME INHIBITORS | EP14753856.5 | 2014-02-20 | EP2958940A2 | 2015-12-30 | BAMDAD, Cynthia; SMAGGHE, Benoit |
| The present application discloses inhibitors of NME family of proteins. | ||||||
| 19 | REPROGRAMMING CANCER CELLS | EP11796473 | 2011-06-16 | EP2582399A4 | 2015-04-15 | BAMDAD CYNTHIA |
| The present describes a method of treating a patient with cancer or at risk of developing cancer with at least regulatory element that induces differentiation of cells. | ||||||
| 20 | REPROGRAMMING CANCER CELLS | EP17171175.7 | 2011-06-16 | EP3228629A1 | 2017-10-11 | Bamdad, Cynthia |
The present describes a method of treating a patient with cancer or at risk of developing cancer with at least regulatory element that induces differentiation of cells.
|
||||||
QQ群二维码
意见反馈
意见反馈